{"id":399,"date":"2021-02-01T13:50:02","date_gmt":"2021-02-01T13:50:02","guid":{"rendered":"https:\/\/magnipharma.kamvitec.com\/?page_id=399"},"modified":"2021-03-11T10:58:54","modified_gmt":"2021-03-11T10:58:54","slug":"news","status":"publish","type":"page","link":"https:\/\/magnipharma.lv\/en\/news\/","title":{"rendered":"News"},"content":{"rendered":"<div class=\"onenews\">\n<p>Patient safety in hospitals can be compromised by preventable adverse events (AE). Among the preventable AEs, hospital-acquired infections (HAIs) are one of the most burdensome, contributing to not only poorer patient outcomes but institutional burden through direct financial losses and increased patient length of stay. \u2026 <br \/>\n<a class=\"wp-embed-more\" href=\"https:\/\/magnipharma.kamvitec.com\/what-is-the-role-of-technology-in-improving-patient-safety\/\" target=\"_top\" rel=\"noopener\">Continue reading<\/a><\/p>\n<\/div>\n<div class=\"onenews\">\n<p>There has been much debate and controversy surrounding the UK test and trace policy since the start of the COVID-19 pandemic. Through these challenging times we have seen a focus on expanding the capacity for COVID-19 testing and \u2026 <br \/>\n<a class=\"wp-embed-more\" href=\"https:\/\/magnipharma.kamvitec.com\/how-point-of-care-testing-will-form-part-of-everyday-life-through-this-covid-19-response-and-beyond\/\" target=\"_top\" rel=\"noopener\">Continue reading<\/a><\/p>\n<\/div>\n<div class=\"onenews\">\n<p>Hetero announces the approval and launch of first generic \u2018COVIFOR\u2019 (Remdesivir) in India for the treatment of Covid-19. <br \/>\n<a class=\"wp-embed-more\" href=\"https:\/\/magnipharma.kamvitec.com\/wp-content\/uploads\/2021\/03\/Hetero_Remdesivir_Launch_FINAL_21062020.pdf\" target=\"_top\" rel=\"noopener\">Continue reading<\/a><\/p>\n<\/div>\n<div class=\"onenews\">\n<p>Hetero announces the launch of \u2018Favivir\u2019 (Favipiravir 200 mg) in India to treat mild to moderate Covid-19. <br \/>\n<a class=\"wp-embed-more\" href=\"https:\/\/magnipharma.kamvitec.com\/wp-content\/uploads\/2021\/03\/Hetero-Announces-the-launch-of-Favivir-in-India.pdf\" target=\"_top\" rel=\"noopener\">Continue reading<\/a><\/p>\n<\/div>\n<div class=\"onenews\">\n<p class=\"wp-embed-heading\">Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib) Roche VENTANA ALK (D5F3) CDx Assay stain image About 235,000 people in the US will be diagnosed with lung cancer in 2021, with non-small cell lung cancer (NSCLC) accounting for 84 percent of \u2026 <br \/>\n<a class=\"wp-embed-more\" href=\"https:\/\/magnipharma.kamvitec.com\/roche-receives-fda\/\" target=\"_top\" rel=\"noopener\">Continue reading<\/a><\/p>\n<\/div>\n<div class=\"onenews\">\n<p>Donating during COVID-19 \u201cOPI introduced several safety changes to give us donors confidence about hygiene and social distancing,\u201d says Dean, who has continued to donate during the pandemic. Read the story below \u201cI didn\u2019t think about donating until somebody else\u2019s donation saved my wife\u2019s life,\u201d says Dean, a retired army officer. \u201cDanica, my wife, was \u2026\u00a0<br \/>\n<a class=\"wp-embed-more\" href=\"https:\/\/magnipharma.kamvitec.com\/news3\/\" target=\"_top\" rel=\"noopener\">Continue reading<\/a><\/p>\n<\/div>\n<div class=\"onenews\">\n<p class=\"wp-embed-heading\">Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released \u00a0 An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data conducted Jan. 21. The vaccine, called Ad.26.COV2.S or JNJ-78436725 requires \u2026 <br \/>\n<a class=\"wp-embed-more\" href=\"https:\/\/magnipharma.kamvitec.com\/news2\/\" target=\"_top\" rel=\"noopener\">Continue reading<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Patient safety in hospitals can be compromised by preventable adverse events (AE). Among the preventable AEs, hospital-acquired infections (HAIs) are one of the most burdensome, contributing to not only poorer patient outcomes but institutional burden through direct financial losses and increased patient length of stay. \u2026 Continue reading There has been much debate and controversy [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":10,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-399","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/magnipharma.lv\/en\/wp-json\/wp\/v2\/pages\/399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/magnipharma.lv\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/magnipharma.lv\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/magnipharma.lv\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/magnipharma.lv\/en\/wp-json\/wp\/v2\/comments?post=399"}],"version-history":[{"count":30,"href":"https:\/\/magnipharma.lv\/en\/wp-json\/wp\/v2\/pages\/399\/revisions"}],"predecessor-version":[{"id":556,"href":"https:\/\/magnipharma.lv\/en\/wp-json\/wp\/v2\/pages\/399\/revisions\/556"}],"wp:attachment":[{"href":"https:\/\/magnipharma.lv\/en\/wp-json\/wp\/v2\/media?parent=399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}